AB-1001 is an experimental gene therapy developed for
Huntington's disease. It is intended to increase the production of the
CYP46A1 enzyme and cholesterol levels in the brain.[1][2]
AB-1001 is an experimental gene therapy developed for
Huntington's disease. It is intended to increase the production of the
CYP46A1 enzyme and cholesterol levels in the brain.[1][2]